EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Practice Guideline
PubMed
27338776
DOI
10.1136/annrheumdis-2016-209133
PII: S0003-4967(24)01713-8
Knihovny.cz E-resources
- Keywords
- Corticosteroids, Cyclophosphamide, Disease Activity, Systemic vasculitis, Treatment,
- MeSH
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis drug therapy pathology MeSH
- Biopsy standards MeSH
- Immunosuppressive Agents therapeutic use MeSH
- Remission Induction methods MeSH
- Humans MeSH
- Disease Management * MeSH
- Retreatment methods MeSH
- Recurrence MeSH
- Plasma Exchange MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Practice Guideline MeSH
- Names of Substances
- Immunosuppressive Agents MeSH
In this article, the 2009 European League Against Rheumatism (EULAR) recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) have been updated. The 2009 recommendations were on the management of primary small and medium vessel vasculitis. The 2015 update has been developed by an international task force representing EULAR, the European Renal Association and the European Vasculitis Society (EUVAS). The recommendations are based upon evidence from systematic literature reviews, as well as expert opinion where appropriate. The evidence presented was discussed and summarised by the experts in the course of a consensus-finding and voting process. Levels of evidence and grades of recommendations were derived and levels of agreement (strengths of recommendations) determined. In addition to the voting by the task force members, the relevance of the recommendations was assessed by an online voting survey among members of EUVAS. Fifteen recommendations were developed, covering general aspects, such as attaining remission and the need for shared decision making between clinicians and patients. More specific items relate to starting immunosuppressive therapy in combination with glucocorticoids to induce remission, followed by a period of remission maintenance; for remission induction in life-threatening or organ-threatening AAV, cyclophosphamide and rituximab are considered to have similar efficacy; plasma exchange which is recommended, where licensed, in the setting of rapidly progressive renal failure or severe diffuse pulmonary haemorrhage. These recommendations are intended for use by healthcare professionals, doctors in specialist training, medical students, pharmaceutical industries and drug regulatory organisations.
Department of Internal Medicine Hôpital Saint Louis Université Paris 7 René Diderot Paris France
Department of Nephrology 1st School of Medicine Charles University Prague Czech Republic
Department of Nephrology Lund University Skåne University Hospital Lund and Malmö Sweden
Department of Ophthalmology School of Medicine Ankara University Ankara Turkey
Department of Otorhinolaryngology Head and Neck Surgery University of Kiel Kiel Germany
Department of Pathology Leiden University Medical Center Leiden The Netherlands
Department of Rheumatology Norfolk and Norwich University Hospital Norwich UK
Immunologie Zentrum Zürich Zürich Switzerland
Lupus and Vasculitis Unit Addenbrooke's Hospital Cambridge UK
Nephrology Unit University Hospital of Parma Parma Italy
Rheumazentrum Schleswig Holstein Mitte Neumünster Germany
Trinity Health Kidney Centre Tallaght Hospital Dublin Ireland
References provided by Crossref.org
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis
